Quick Answer
Jasper Therapeutics, Inc. reported Net Income of -$75.80 million for fiscal year 2025.
Jasper Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$75.80M | -6.4% |
| 2024 | -$71.27M | -10.6% |
| 2023 | -$64.47M | -71.1% |
| 2022 | -$37.69M | -23.0% |
| 2021 | -$30.64M | +3.3% |
| 2020 | -$31.67M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$18.74M | -0.5% | +29.9% |
| June 30, 2025 | -$26.72M | -83.2% | -25.8% |
| March 31, 2025 | -$21.24M | -54.7% | -14.0% |
| September 30, 2024 | -$18.64M | +61.1% | -27.8% |
| June 30, 2024 | -$14.58M | +9.3% | -6.2% |
| March 31, 2024 | -$13.73M | +3.7% | +71.3% |
| September 30, 2023 | -$47.88M | -303.6% | -197.8% |
| June 30, 2023 | -$16.08M | -54.6% | -12.8% |
- Jasper Therapeutics, Inc. showed a decrease of -6.4% in Net Income compared to the prior fiscal year.
- Over the 2020–2025 period, Jasper Therapeutics, Inc.’s net income has declined by 139.4% (from -$31.67 million to -$75.80 million).
- The most recent figure is from Jasper Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: